Cellectar Biosciences (CLRB) Stock Forecast, Price Target & Predictions
CLRB Stock Forecast
Cellectar Biosciences stock forecast is as follows: an average price target of $12.00 (represents a 669.23% upside from CLRB’s last price of $1.56) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
CLRB Price Target
The average price target for Cellectar Biosciences (CLRB) is $12.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $12.00. This represents a potential 669.23% upside from CLRB's last price of $1.56.
CLRB Analyst Ratings
According to 1 Wall Street analysts, Cellectar Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for CLRB stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Cellectar Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Mar 28, 2024 | Jeff Jones | Oppenheimer | $12.00 | $3.63 | 230.12% | 669.23% |
The latest Cellectar Biosciences stock forecast, released on Mar 28, 2024 by Jeff Jones from Oppenheimer, set a price target of $12.00, which represents a 230.12% increase from the stock price at the time of the forecast ($3.63), and a 669.23% increase from CLRB last price ($1.56).
Cellectar Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 1 |
| Avg Price Target | - | - | $12.00 |
| Last Closing Price | $1.56 | $1.56 | $1.56 |
| Upside/Downside | -100.00% | -100.00% | 669.23% |
In the current month, the average price target of Cellectar Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cellectar Biosciences's last price of $1.56. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| May 14, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 28, 2024 | Oppenheimer | Outperform | Outperform | Hold |
Cellectar Biosciences's last stock rating was published by Oppenheimer on May 14, 2024. The company gave CLRB a "Outperform" rating, the same as its previous rate.
Cellectar Biosciences Financial Forecast
Cellectar Biosciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $8.33K | $30.97K | - | - |
| Avg Forecast | $28.00M | $21.00M | $18.00M | $12.00M | $8.00M | $6.00M | $1.50M | - | $1.75M | - | - | - | $12.00K | $30.00K | $7.40K | $12.58K |
| High Forecast | $28.00M | $21.00M | $18.00M | $12.00M | $8.00M | $6.00M | $1.50M | - | $1.75M | - | - | - | $14.40K | $36.00K | $8.88K | $15.10K |
| Low Forecast | $28.00M | $21.00M | $18.00M | $12.00M | $8.00M | $6.00M | $1.50M | - | $1.75M | - | - | - | $9.60K | $24.00K | $5.92K | $10.07K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 1.03% | - | - |
Cellectar Biosciences's average Quarter revenue forecast for Mar 24 based on 0 analysts is -, with a low forecast of -, and a high forecast of -. CLRB's average Quarter revenue forecast represents a -100.00% decrease compared to the company's last Quarter revenue of $8.33K (Mar 10).
Cellectar Biosciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $5.38M | $-1.81M | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.21M | $-4.20M | $-953.85K |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | $-1.77M | $-3.36M | $-763.08K |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | $-2.65M | $-5.04M | $-1.14M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.82% | - | - |
0 analysts predict CLRB's average Quarter EBITDA for Mar 24 to be -, with a high of - and a low of -. This is -100.00% lower than Cellectar Biosciences's previous annual EBITDA (Mar 10) of $5.38M.
Cellectar Biosciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $5.35M | $-1.81M | - | - |
| Avg Forecast | $1.12M | $-1.87M | $-3.00M | $-5.99M | $-7.49M | $-8.24M | $-10.11M | $-9.74M | $-12.73M | $-12.36M | $-11.98M | $-14.48M | $7.70M | $-2.22M | $-4.21M | $-954.87K |
| High Forecast | $1.12M | $-1.87M | $-3.00M | $-5.99M | $-7.49M | $-8.24M | $-10.11M | $-9.74M | $-12.73M | $-9.18M | $-11.98M | $-14.48M | $9.25M | $-1.77M | $-3.36M | $-763.90K |
| Low Forecast | $1.12M | $-1.87M | $-3.00M | $-5.99M | $-7.49M | $-8.24M | $-10.11M | $-9.74M | $-12.73M | $-15.18M | $-11.98M | $-14.48M | $6.16M | $-2.66M | $-5.05M | $-1.15M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.69% | 0.82% | - | - |
Cellectar Biosciences's average Quarter net income forecast for Mar 24 is $-14.48M, with a range of $-14.48M to $-14.48M. CLRB's average Quarter net income forecast represents a -370.60% decrease compared to the company's last Quarter net income of $5.35M (Mar 10).
Cellectar Biosciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $644.76K | $476.20K | - | - |
| Avg Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cellectar Biosciences's average Quarter SG&A projection for Mar 24 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to CLRB last annual SG&A of $644.76K (Mar 10).
Cellectar Biosciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Mar 10 | Mar 09 | Mar 08 | Oct 05 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | 1 | - | - | - | 10 | 16 | 11 | 16 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $161.84K | $-235.40K | - | - |
| Avg Forecast | $0.03 | $-0.05 | $-0.08 | $-0.16 | $-0.20 | $-0.22 | $-0.27 | $-0.26 | $-0.34 | $-0.33 | $-0.32 | $-0.49 | $-220.32K | $-336.60K | $-235.62K | $-122.40K |
| High Forecast | $0.03 | $-0.05 | $-0.08 | $-0.16 | $-0.20 | $-0.22 | $-0.27 | $-0.26 | $-0.34 | $-0.25 | $-0.32 | $-0.49 | $-176.26K | $-269.28K | $-188.50K | $-97.92K |
| Low Forecast | $0.03 | $-0.05 | $-0.08 | $-0.16 | $-0.20 | $-0.22 | $-0.27 | $-0.26 | $-0.34 | $-0.41 | $-0.32 | $-0.49 | $-264.38K | $-403.92K | $-282.74K | $-146.88K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -0.73% | 0.70% | - | - |
According to 0 Wall Street analysts, Cellectar Biosciences's projected average Quarter EPS for Mar 24 is $-0.49, with a low estimate of $-0.49 and a high estimate of $-0.49. This represents a -100.00% decrease compared to CLRB previous annual EPS of $161.84K (Mar 10).
Cellectar Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| CLRB | Cellectar Biosciences | $1.56 | $12.00 | 669.23% | Buy |
| LUMO | Lumos Pharma | $4.32 | $16.50 | 281.94% | Buy |
| NXTC | NextCure | $1.30 | $3.00 | 130.77% | Buy |
| BNTC | Benitec Biopharma | $10.66 | $20.33 | 90.71% | Buy |
| CAPR | Capricor Therapeutics | $18.92 | $35.75 | 88.95% | Buy |
| BOLT | Bolt Biotherapeutics | $0.57 | $1.00 | 75.44% | Hold |
| MNPR | Monopar Therapeutics | $19.00 | $29.50 | 55.26% | Buy |
| LBPH | Longboard Pharmaceuticals | $59.77 | $61.00 | 2.06% | Hold |